PERK eIF2alpha kinase regulates neonatal growth by controlling the expression of circulating insulin-like growth factor-I derived from the liver.
Document Type
Article
Publication Date
2003
Keywords
Biometry, Body-Weight, Cell-Count, Cell-Division, Chondrocytes, Gene-Expression-Regulation, Growth-Disorders, Growth-Plate, Insulin-Like-Growth-Factor-I, Liver, Mice-Knockout, Mice-Transgenic, RNA-Messenger, Tibia, Transcription-Genetic
First Page
3505
Last Page
3513
JAX Source
Endocrinology 2003 Aug; 144(8):3505-3513.
Abstract
Humans afflicted with the Wolcott-Rallison syndrome and mice deficient for PERK (pancreatic endoplasmic reticulum eIF2alpha kinase) show severe postnatal growth retardation. In mice, growth retardation in Perk-/- mutants is manifested within the first few days of neonatal development. Growth parameters of Perk-/- mice, including comparison of body weight to length and organ weights, are consistent with proportional dwarfism. Tibia growth plates exhibited a reduction in proliferative and hypertrophic chondrocytes underlying the longitudinal growth retardation. Neonatal Perk-/- deficient mice show a 75% reduction in liver IGF-I mRNA and serum IGF-I within the first week, whereas the expression of IGF-I mRNA in most other tissues is normal. Injections of IGF-I partially reversed the growth retardation of the Perk-/- mice, whereas GH had no effect. Transgenic rescue of PERK activity in the insulin- secreting beta-cells of the Perk-/- mice reversed the juvenile but not the neonatal growth retardation. We provide evidence that circulating IGF-I is derived from neonatal liver but is independent of GH at this stage. We propose that PERK is required to regulate the expression of IGF-I in the liver during the neonatal period, when IGF-I expression is GH-independent, and that the lack of this regulation results in severe neonatal growth retardation.
Recommended Citation
Li Y,
Iida K,
O'Neil J,
Zhang P,
Li S,
Frank A,
Gabai A,
Zambito F,
Liang SH,
Rosen CJ,
Cavener DR.
PERK eIF2alpha kinase regulates neonatal growth by controlling the expression of circulating insulin-like growth factor-I derived from the liver. Endocrinology 2003 Aug; 144(8):3505-3513.